Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

Prime Medicine, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

MONTREAL, AUG. 15, 2025 (GLOBE NEWSWIRE) -- PRIME DRINK GROUP CORP. (CSE: PRME) (PRIME OR THE COMPANY) ANNOUNCES THAT FURTHER TO ITS NEWS RELEASE DATE JULY 30, 2025, THE COMPANY VOLUNTARILY APPLIED FOR AND THE COMPANY'S PRINCIPAL REGULATOR, THE BRITISH COLUMBIA SECURITIES COMMISSION (THE BCSC) GRANTED A MANAGEMENT CEASE TRADE ORDER (THE MCTO) DATED JULY 30, 2025, UNDER NATIONAL POLICY 12-203 MANAGEMENT CEASE TRADE ORDERS (NP 12-203) AND PROVIDED THE COMPANY WITH AN EXTENSION TO FILE ITS ANNUAL FINANCIAL STATEMENTS FOR THE PERIOD ENDED MARCH 31, 2025, INCLUDING THE RELATED MANAGEMENT'S DISCUSSION AND ANALYSIS, AND RELATED CERTIFICATIONS ON OR BEFORE JULY 29, 2025 (COLLECTIVELY THE ANNUAL FINANCIAL FILINGS). THE DEADLINE HAS NOW BEEN EXTENDED TO ON OR BEFORE SEPTEMBER 29, 2025.

PRIME DRINK GROUP PROVIDES BI-WEEKLY MCTO STATUS REPORT AND ANNOUNCES CLOSING OF PRIVATE PLACEMENT

-- ANNOUNCED POSITIVE DATA FROM TWO PATIENTS IN PHASE 1/2 CLINICAL TRIAL IN CHRONIC GRANULOMATOUS DISEASE (CGD), PROVIDING CLINICAL PROOF-OF-CONCEPT FOR PRIME EDITING; PLAN TO HAVE REGULATORY INTERACTIONS BASED ON CURRENT DATASET -- -- COMPLETED FOLLOW-ON OFFERING, RAISING $144.2 MILLION IN GROSS PROCEEDS AND EXTENDING CASH RUNWAY INTO 2027 --

PRIME MEDICINE REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

CAMBRIDGE, MASS., AUG. 01, 2025 (GLOBE NEWSWIRE) -- PRIME MEDICINE, INC. (NASDAQ: PRME), A BIOTECHNOLOGY COMPANY COMMITTED TO DELIVERING A NEW CLASS OF DIFFERENTIATED ONE-TIME CURATIVE GENETIC THERAPIES, TODAY ANNOUNCED THE CLOSING OF ITS UNDERWRITTEN PUBLIC OFFERING OF 43,700,000 SHARES OF ITS COMMON STOCK, WHICH INCLUDES THE FULL EXERCISE OF THE UNDERWRITERS' OPTION TO PURCHASE 5,700,000 ADDITIONAL SHARES OF ITS COMMON STOCK, AT A PUBLIC OFFERING PRICE OF $3.30 PER SHARE.

PRIME MEDICINE ANNOUNCES CLOSING OF PUBLIC OFFERING AND FULL EXERCISE OF THE UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES

CAMBRIDGE, MASS., JULY 30, 2025 (GLOBE NEWSWIRE) -- PRIME MEDICINE, INC. (NASDAQ: PRME), A BIOTECHNOLOGY COMPANY COMMITTED TO DELIVERING A NEW CLASS OF DIFFERENTIATED ONE-TIME CURATIVE GENETIC THERAPIES, TODAY ANNOUNCED THE PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 38,000,000 SHARES OF ITS COMMON STOCK AT A PUBLIC OFFERING PRICE OF $3.30 PER SHARE.

PRIME MEDICINE ANNOUNCES PRICING OF PUBLIC OFFERING

MONTREAL, JULY 30, 2025 (GLOBE NEWSWIRE) -- PRIME DRINK GROUP CORP. (CSE: PRME) (PRIME OR THE COMPANY) ANNOUNCES THAT, PURSUANT TO A NOTICE OF VARIATION DATED JULY 29, 2025 (THE NOTICE OF VARIATION), IT HAS EXTENDED THE EXPIRY DATE OF ITS PREVIOUSLY ANNOUNCED RIGHTS OFFERING (THE RIGHTS OFFERING) TO AUGUST 29, 2025. ALL OTHER TERMS OF THE RIGHTS OFFERING REMAIN THE SAME AS DESCRIBED IN THE CIRCULAR (AS DEFINED HEREIN) AND AS ANNOUNCED IN ITS PRESS RELEASE DATED JUNE 18, 2025. A COPY OF THE NOTICE OF VARIATION IS AVAILABLE ON SEDAR+ AT WWW.SEDARPLUS.CA.

PRIME DRINK GROUP EXTENDS EXPIRY DATE OF ITS RIGHTS OFFERING AND ANNOUNCES DELAY IN FILING ANNUAL FINANCIAL STATEMENTS

CAMBRIDGE, MASS., JULY 30, 2025 (GLOBE NEWSWIRE) -- PRIME MEDICINE, INC. (NASDAQ: PRME), A BIOTECHNOLOGY COMPANY COMMITTED TO DELIVERING A NEW CLASS OF DIFFERENTIATED ONE-TIME CURATIVE GENETIC THERAPIES, TODAY ANNOUNCED THAT IT HAS COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF SHARES OF ITS COMMON STOCK. PRIME MEDICINE ALSO INTENDS TO GRANT THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL FIFTEEN PERCENT (15%) OF THE SHARES OF ITS COMMON STOCK OFFERED IN THE PUBLIC OFFERING. ALL OF THE SHARES OF COMMON STOCK IN THE PROPOSED OFFERING ARE TO BE SOLD BY PRIME MEDICINE. THE PROPOSED OFFERING IS SUBJECT TO MARKET AND OTHER CONDITIONS, AND THERE CAN BE NO ASSURANCE AS TO WHETHER OR WHEN THE OFFERING MAY BE COMPLETED, OR AS TO THE ACTUAL SIZE OR TERMS OF THE OFFERING.

PRIME MEDICINE ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BETHESDA, MD.--(BUSINESS WIRE)--TODAY, THE CYSTIC FIBROSIS FOUNDATION ANNOUNCED AN ADDITIONAL INVESTMENT OF UP TO $24 MILLION IN PRIME MEDICINE TO CONTINUE THE DEVELOPMENT OF A GENE EDITING THERAPY FOR PEOPLE WITH CYSTIC FIBROSIS (CF). PRIME MEDICINE USES A GENE EDITING TECHNOLOGY CALLED PRIME EDITING  A TECHNOLOGY THAT ENABLES A WIDE RANGE OF MODIFICATIONS TO THE DNA WITH A HIGH DEGREE OF PRECISION. THE COMPANY  FOUNDED BY DRS. DAVID LIU AND ANDREW ANZALONE, WHO PIONEERED THE DEVELOPMENT OF.

CYSTIC FIBROSIS FOUNDATION COMMITS UP TO AN ADDITIONAL $24 MILLION FOR PRIME MEDICINE TO DEVELOP GENE EDITING THERAPY

-- EXPANDED FUNDING BUILDS ON THE INITIAL AGREEMENT TO ACCELERATE DEVELOPMENT OF PRIME EDITORS FOR CYSTIC FIBROSIS (CF) -- -- PRIME MEDICINE TO RECEIVE UP TO $24 MILLION IN ADDITIONAL FUNDING FROM THE CYSTIC FIBROSIS FOUNDATION -- -- MULTIPLE HOTSPOT PRIME EDITORS MAY BENEFIT MORE THAN 93% OF PEOPLE WITH CF -- CAMBRIDGE, MASS., JULY 16, 2025 (GLOBE NEWSWIRE) -- PRIME MEDICINE, INC. (NASDAQ: PRME), A BIOTECHNOLOGY COMPANY COMMITTED TO DELIVERING A NEW CLASS OF DIFFERENTIATED ONE-TIME CURATIVE GENETIC THERAPIES, TODAY ANNOUNCED THAT THE CYSTIC FIBROSIS FOUNDATION (CF FOUNDATION) HAS AGREED TO PROVIDE THE COMPANY WITH UP TO $24 MILLION IN ADDITIONAL FUNDING TO ACCELERATE THE DEVELOPMENT OF PRIME EDITORS DESIGNED TO PERMANENTLY CORRECT CYSTIC FIBROSIS-RELATED LUNG DISEASE.

PRIME MEDICINE ANNOUNCES ADDITIONAL FUNDING OF UP TO $24 MILLION FROM THE CYSTIC FIBROSIS FOUNDATION TO ADVANCE PRIME EDITING TREATMENTS FOR CYSTIC FIBROSIS

MONTREAL, JULY 04, 2025 (GLOBE NEWSWIRE) -- PRIME DRINK GROUP CORP. (CSE: PRME) (PRIME) ANNOUNCES THAT IT HAS CHANGED ITS AUDITORS FROM MNP LLP ("FORMER AUDITOR") TO HORIZON ASSURANCE LLP ("SUCCESSOR AUDITOR"). THE FORMER AUDITOR RESIGNED AS THE AUDITOR OF THE COMPANY ON ITS OWN INITIATIVE EFFECTIVE JUNE 25, 2025, AND THE BOARD OF DIRECTORS OF THE COMPANY APPOINTED THE SUCCESSOR AUDITOR AS THE COMPANY'S AUDITOR EFFECTIVE JUNE 30, 2025, UNTIL THE NEXT ANNUAL GENERAL MEETING OF THE COMPANY.

PRIME DRINK GROUP ANNOUNCES CHANGE OF AUDITOR

MONTREAL, JULY 02, 2025 (GLOBE NEWSWIRE) -- PRIME DRINK GROUP CORP. (CSE: PRME) (PRIME OR THE COMPANY) ANNOUNCES THAT IT WILL PROCEED WITH A BEST EFFORTS NON-BROKERED PRIVATE PLACEMENT OFFERING OF UNITS OF THE COMPANY (THE UNITS) TO RAISE MAXIMUM GROSS PROCEEDS OF $1,000,000 (THE UNIT OFFERING).

PRIME DRINK GROUP ANNOUNCES PRIVATE PLACEMENT

MONTREAL, JUNE 18, 2025 (GLOBE NEWSWIRE) -- PRIME DRINK GROUP CORP. (CSE: PRME) (PRIME OR THE COMPANY) ANNOUNCES THAT IT IS UNDERTAKING A RIGHTS OFFERING (THE RIGHTS OFFERING). THE COMPANY WILL BE OFFERING A MAXIMUM OF 353,409,888 RIGHTS (THE RIGHTS) TO HOLDERS (THE SHAREHOLDERS) OF ITS COMMON SHARES (THE SHARES) AS AT THE CLOSE OF BUSINESS ON THE RECORD DATE OF JUNE 25, 2025 (THE RECORD DATE) ON THE BASIS OF ONE (1) RIGHT FOR EACH ONE (1) SHARE HELD. EACH ONE (1) RIGHT WILL ENTITLE THE HOLDER TO SUBSCRIBE FOR ONE SHARE (EACH, A RIGHTS SHARE) AT THE SUBSCRIPTION PRICE OF $0.0825 PER RIGHTS SHARE.

Prime Medicine, Inc.

PRME

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Prime Medicine, Inc.

PRME.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

PRME